Figure 2From: Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trialThe proportion of responders. The response rates of 25U group (70.4%) and 75U group (86.2%) were significantly higher than placebo group (32.1%) at week 8 (*P < 0.017). There was no significant difference between 25U and 75U groups (P > 0.05).Back to article page